Novo Nordisk | NVO - Current Liabilities


Novo Nordisk reported DKK32.79B in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
Aurora Cannabis CAD 66.93M 79M Mar/2026
Bausch Health Companies USD 4.53B 350M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Canopy Growth CAD 158.44M 60.15M Mar/2026
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Novo Nordisk DKK 32.79B 203.33B Jun/2025
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Phibro Animal Health USD 281.87M 500K Mar/2026
Prestige Brands USD 120.92M 18.63M Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
Zoetis USD 2.05B 182M Mar/2026